BeyondSpring (BYSI) vs Tvardi Therapeutics (TVRD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Tvardi Therapeutics (TVRD) has outperformed BeyondSpring (BYSI) over the past year, losing 74.8% versus a loss of 82.8%. Over five years, BYSI leads with a -97.7% price change compared with -99.8% for TVRD. BeyondSpring is the larger company by market cap ($13.7 million vs $13.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BYSI | TVRD |
|---|---|---|
| Share price | $0.33 | $0.9893 |
| Market cap | $13.66M | $13.22M |
| 1-day change | -24.49% | +4.57% |
| YTD return | -79.75% | -76.99% |
| 1-year return | -82.77% | -74.76% |
| 5-year return | -97.70% | -99.79% |
| EPS (TTM) | $-0.20 | $-2.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Net income (latest FY) | $-1.01M | $-18.21M |
| 52-week high | $2.44 | $5.69 |
| 52-week low | $0.299 | $0.773 |
| Distance from 52-week high | -86.48% | -82.61% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +835.00% |
| Average volume | 261.79K | 235.95K |
| Shares outstanding | 41.41M | 13.36M |
| Employees | 44 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BeyondSpring
BYSI stock →BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees
About Tvardi Therapeutics
TVRD stock →Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
BYSI vs TVRD FAQ
Which is bigger, BeyondSpring or Tvardi Therapeutics?
BeyondSpring (BYSI) is larger, with a market capitalization of $13.66M compared with $13.22M for Tvardi Therapeutics (TVRD).
Which stock has performed better over the past year, BYSI or TVRD?
TVRD returned -74.76% over the past 12 months, compared with -82.77% for BYSI (price return, excluding dividends). Past performance does not predict future results.
Are BeyondSpring and Tvardi Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.